A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Masitinib (Primary) ; Donepezil; Galantamine; Memantine; Rivastigmine
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
Most Recent Events
- 23 Jun 2025 Results presented in the AB Science Media Release.
- 30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
- 29 Jul 2021 According to an AB Science media release, the full abstract will be published in a supplement of Alzheimer's & Dementia (the journal of the Alzheimer's Association).